WO1999004790A1 - Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative - Google Patents

Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative Download PDF

Info

Publication number
WO1999004790A1
WO1999004790A1 PCT/JP1998/003172 JP9803172W WO9904790A1 WO 1999004790 A1 WO1999004790 A1 WO 1999004790A1 JP 9803172 W JP9803172 W JP 9803172W WO 9904790 A1 WO9904790 A1 WO 9904790A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition according
water
surfactant
pranlukast
hydrate
Prior art date
Application number
PCT/JP1998/003172
Other languages
French (fr)
Inventor
Shinichi Yasueda
Tadashi Terai
Takahiro Ogawa
Yoshinori Ii
Original Assignee
Ono Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Priority to DE69819900T priority Critical patent/DE69819900T2/en
Priority to US09/463,211 priority patent/US6274609B1/en
Priority to AT98932526T priority patent/ATE254457T1/en
Priority to KR1020007000683A priority patent/KR20010022113A/en
Priority to CA002296562A priority patent/CA2296562A1/en
Priority to EP98932526A priority patent/EP0996442B1/en
Publication of WO1999004790A1 publication Critical patent/WO1999004790A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as a main component 4-oxo-8- [4- (4- phenylbutoxy)benzoylamino] -2- (tetrazol-5-yl) -4H-1-benzopyran or its hydrate.
  • a pharmaceutical composition comprising as a main component 4-oxo-8- [4- (4- phenylbutoxy)benzoylamino] -2- (tetrazol-5-yl) -4H-1-benzopyran or its hydrate.
  • an aqueous liquid pharmaceutical composition containing the benzopyran derivative or its hydrate in higher concentration and having good properties.
  • a pharmacologically active component should be present in concentration of about 0.01 to 0.1%.
  • 4- oxo-8- [4- (4-phenylbutoxy)benzoylamino] -2- (tetrazol-5-yl) -4H-1- benzopyran and its hydrate (hereinafter, they are referred to as "pranlukast" all together, unless otherwise stated) have very low water-solubility, which makes it very difficult to prepare a useful aqueous liquid pharmaceutical composition thereof. Then, the use
  • pranlukast dissolves in water in concentration of, at highest, about 0.01%.
  • the main object of the present invention is to promote solubilization or suspension of pranlukast in water, thereby providing an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.
  • Fig. 1 is a graph illustrating the relation between hydroxypropylmethyl cellulose (HPMC) concentration and time required for re-dispersion of pranlukast.
  • Fig. 2 is a graph illustrating the results of the test for inhibitory activity on conjunctival eosinocyte infiltration hereinafter.
  • the present inventors have extensively studied to promote solubilization or suspension of pranlukast in water and, consequently, have found that the desired solubilization or suspension can be obtained by using at least one component selected from surfactants and specific high-molecular weight substances.
  • the present inventors have succeeded in preparing the desired aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties, and have completed the present invention.
  • an aqueous liquid pharmaceutical composition which comprises 4-oxo-8- [4- (4-phenylbutoxy) benzoylamino] -2-
  • aqueous liquid pharmaceutical composition of the present invention is an aqueous solution containing pranlukast and a surfactant .
  • the composition further contains a stabilizer.
  • aqueous liquid pharmaceutical composition of the present invention is an aqueous suspension containing pranlukast and at least one component selected from the group consisting of water-soluble cellulose derivatives and water-soluble vinyl polymers.
  • the suspension may further contain a surfactant.
  • the suspension contains a relatively small amount of a surfactant together with the water-soluble high-molecular weight substance.
  • aqueous liquid pharmaceutical compositions have good re-dispersibility over a long time and are stable .
  • they can contain higher concentration of pranlukast. Then, they can be useful as eye drops, nasal drops, injectable preparations, internal medicine and the like and can be used as an eosinocyte infiltration inhibitor.
  • the amount of pranlukast to be formulated in the composition is not specifically limited but, in case of an aqueous solution, it is formulated in an amount of 0.2 w/v% or less, normally, 0.001 to 0.2 w/v%, preferably 0.005 to 0.1 w/v% based on the total weight of the composition and, in case of an aqueous suspension, 0.01 to 5.0 w/v%, preferably 0.1 to 2.0 w/v% based on the total weight of the composition, in terms of its 1/2 hydrate.
  • the surfactants to be used are at least one member selected from nonionic surfactants, cationic surfactants and anionic surfactants.
  • nonionic surfactants it is preferred to use those having HLB of 10 to 18.
  • the nonionic surfactants include polyoxyethylene sorbitan fatty acid ester (e.g., Polysorbate 80, Polysorbate 60, Polysorbate 40, etc.), polyoxyethylene hydrogenated castor oil (e.g., polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene castor oil 40, etc.), polyoxyethylene alkylphenyl formaldehyde condensate (e.g., Tyloxapol, etc.), polyoxyethylene polyoxypropylene block copolymer (e.g., Poloxamer 188, Poloxamer 403, etc.) and sucrose ester of fatty acid (e.g., Ryutosugar ester P-1570 and S-1570 manufactured by Mitsubishi Chemical Foods), among others.
  • cationic surfactants examples include quaternary ammonium salt (e.g., benzalkonium chloride, etc.), among others.
  • anionic surfactants include alkyl sulfate (e.g., sodium lauryl sulfate, etc.), among others.
  • the surfactant can be used alone or in combination of two or more thereof and, normally, in case of an aqueous solution, the surfactant (s) are formulated in an amount of 0.5 to 8 w/v%, preferably 1 to 5 w/v%, more preferably 2 to 4 w/v% based on the total weight of the composition. And, in this case, the proportion of the surfactant (s) to pranlukast is such that 5 to 100 parts, preferably 10 to 60 parts by weight of the surfactant (s) are formulated per 1 part of pranlukast (1/2 hydrate) .
  • the surfactant (s) are formulated in an amount of 0.0001 to 0.2 w/v%, preferably 0.001 to 0.2 w/v%, more preferably 0.01 to 0.2 w/v% based on the total weight of the composition together with the water-soluble high-molecular weight substance as described hereinafter.
  • the proportion of the surfactant (s) to pranlukast is such that 0.0001 to 0.2 part, preferably 0.001 to 0.2 part, more preferably 0.01 to 0.2 part by weight of the surfactant (s) are formulated per 1 part of pranlukast (1/2 hydrate) .
  • the composition when the composition is in the form of an aqueous solution, normally, pH of the composition is adjusted to 6 or higher, preferably 6 to 9, more preferably 6 to 8. Further, in addition to the surfactants, it is preferred to formulate at least one stabilizer selected from anti-oxidants and chelating agents in an amount of about 0.001 to 0.1 w/v%, thereby improving stability of pranlukast.
  • antioxidants there are, for example, anti- oxidants such as butylated hydroxytoluene, butylated hydroxyanisole, etc. and chelating agents such as sodium edetate, etc . They can be used alone or in combination of two or more thereof .
  • the water-soluble cellulose derivatives used in the present invention include at least one member selected from methylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxypropylmethyl cellulose.
  • the water-soluble vinyl polymers used in the present invention include at least one member selected from polyvinyl pyrrolidone K25, polyvinyl pyrrolidone K30, polyvinyl pyrrolidone K90, polyvinyl alcohol and carboxyvinyl polymer.
  • These water-soluble high-molecular weight substances can be used alone or in combination of two or more thereof.
  • these water-soluble high-molecular weight substances can be used together with one or more surfactants, thereby further improving re-dispersibility of the aqueous suspension, in particular, after storage.
  • the water-soluble cellulose derivatives and the water-soluble vinyl polymers function, in particular, as a suspending agent of the aqueous liquid pharmaceutical composition in the form of a suspension. Then, they are formulated in an amount of 0.00001 to 0.1 w/v%, preferably 0.00005 to 0.05 w/v% based on the total weight of the composition. 7 ⁇ nd, the proportion of the water-soluble high-molecular weight substance (s) to pranlukast is such that 0.0001 to 0.1 part by weight, preferably 0.0005 to 0.02 part by weight of the water-soluble high-molecular weight substance (s) are formulated per 1 part by weight of pranlukast (1/2 hydrate) .
  • suspending agent In a liquid pharmaceutical composition, such suspending agent is generally used in concentration ranging from 0.1 to 4 w/v% based on the total weight of the composition. In view of this, it is very surprising that the suspending agent functions even in such a small amount as in the present invention.
  • pH of the composition may be within, for example, the range normally employed for eye drops (e.g., pH 4 to 9, preferably pH 5 to 8) .
  • the aqueous liquid pharmaceutical composition may further contain suitable additives, for example, an isotonic agent such as inorganic salt (e.g., sodium chloride, boric acid, potassium chloride, etc.) and polyhydric alcohol (e.g., glycerin, mannitol, sorbitol, etc.); a buffer solution such as borate buffer solution, phosphate buffer solution, acetate buffer solution, citrate buffer solution, Tris buffer solution, etc. and buffer agent such as a ino acid (e.g., glutamic acid, ⁇ -
  • an isotonic agent such as inorganic salt (e.g., sodium chloride, boric acid, potassium chloride, etc.) and polyhydric alcohol (e.g., glycerin, mannitol, sorbitol, etc.); a buffer solution such as borate buffer solution, phosphate buffer solution, acetate buffer solution, citrate buffer solution, Tris buffer solution, etc. and buffer agent such as a ino
  • aminocapronic acid etc .
  • a chelating agent such as sodium edetate, citric acid, etc.
  • a preservative such as quaternary ammonium salt (e.g., benzalkonium chloridie, benzethonium chloride, etc.), p-hydroxybenzoate (methyl p-hydroxybenzoate, ethyl p- hydroxybenzoate, propyl p-hydroxybenzoate, butyl p- hydroxybenzoate, etc.), sorbic acid, chlorobutanol, sodium edetate, boric acid, etc., and the like.
  • quaternary ammonium salt e.g., benzalkonium chloridie, benzethonium chloride, etc.
  • p-hydroxybenzoate methyl p-hydroxybenzoate, ethyl p- hydroxybenzoate, propyl p-hydroxybenzoate, butyl p- hydroxybenzoate, etc.
  • an isotonic agent can be formulated in an amount of 0.5 to 6.5 w/v% based on the total weight of the composition.
  • 0.01 to 1.0 w/v% of a buffer and 0.001 to 0.1 w/v% of a chelating agent can be formulated based on the total weight of the composition.
  • the aqueous liquid pharmaceutical composition of the present invention can be prepared in the form of an aqueous solution or suspension such as eye drops, nasal drops, injectable preparations, internal medicine and the like according to a per se known method.
  • the composition can be prepared by adding the solubilizing agent and/or suspending agent, a buffer, an isotonic agent and a preservative to sterilized purified water and, if necessary, heating to dissolve them.
  • the desired liquid pharmaceutical composition can be prepared by dissolving or suspending pranlukast in the resultant solution.
  • the aqueous liquid pharmaceutical composition of the present invention has eosinocyte infiltration inhibitory activity and is useful as an eosinocyte infiltration inhibitor. Then, it can be used for prophylaxis and therapy of seasonal or year-round allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, contact blephroconjunctivits, keratitis, scleritis, uveitis, eye itch, allergic rhinitis, sneeze, nasal itching, nasal hypersensitivity, nasofrontal eczema, nasal obstruction and the like.
  • composition is topically or systemically administered once to six times per day at a daily dosage of 20 to 100 ⁇ g/ml of pranlukast.
  • pranlukast used is the 1/2 hydrate and all the “percents" are by weight unless otherwise stated.
  • Pranlukast (manufactured by Ono Pharmaceutical Co., Ltd.) was suspended in 0.1% borate buffer (pH 9 or 8) or 0.1% phosphate buffer (pH8or7) at concentration of 0.1 w/v% . Likewise, pranlukast was suspended in each 0.5% solution of surfactants
  • polysorbate 80 polysorbate 60, polysorbate 40, polyoxyethylene hydrogenated castor oil 60, Tyloxapol, benzalkonium chloride, and sodium lauryl sulfate
  • water-soluble vinyl polymers polyvinyl pyrrolidione K30, and polyvinyl alcohol
  • cyclodextrins ⁇ - cyclodextrin, y -cyclodextrin, and 2HP- ⁇ -cyclodextrin
  • Polysorbate 80 was dissolved in 0.1% phosphate buffer and/or 0.1% acetate buffer at concentration of 0.5%. Pranlukast
  • Solubility of pranlukast is shown in Table 2. As the rise in pH, solubility of pranlukast was increased.
  • Polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 (hereinafter abbreviated as HCO-60) was dissolved in 0.1% phosphate buffer at concentration of 1.0%, 2.0%, 3.0% or 4.0%.
  • Pranlukast manufactured by Ono Pharmaceutical Co., Ltd.
  • Each suspension was filled in a glass ampoule and shaken overnight (for about 15 hours) at25°C. After shaking, the suspension was filtered with a membrane filter of 0.22 ⁇ m pore size and pranlukast in the filtrate was determined by HPLC. Results Regarding each nonionic surfactant at each concentration, solubility of pranlukast is shown in Table 3 Table 3
  • solubility of pranlukast was increased as increase in the amount of polysorbate 80 and polyoxyethylene hydrogenated castor oil 60.
  • solutions A to F were prepared. Each solution was filled in a 5 ml-glass ampoule and stored at 60°C for 2 weeks. After 2 weeks, pranlukast in the solution was determined by HPLC and its residual rate was calculated.
  • HPMC hydroxyporpylmethyl cellulose
  • Results Fig. 1 illustrates the relation between HPMC concentration and time required for re-dispersion.
  • Pranlukast was suspended in a vehicle containing 0.1% of sodium dihydrogen phosphate, 0.9% of sodium chloride and 0.1% polysorbate 80 (pH 7) at concentration of 1.0%.
  • physiological saline solution was used as a control.
  • the guinea pigs were sensitized by administering a mixture of 10 ⁇ g of ovalbumin (hereinafter referred to as OA) and 30 mg of aluminum hydroxide gel intraperitoneally . 14 Days after sensitization, 10 ⁇ l of 2.5% OA antigen solution was instilled in both eyes of the guinea pigs to cause conjunctivitis (primary challenge) . Likewise, 24 hours after the primary challenge, 2.5% OA antigen solution was instilled to cause conjunctivitis again (secondary challenge) .
  • OA ovalbumin
  • each guinea pig was slaughtered, the upper and lower lids were removed from the periosteum and the lids together with the eyeball were extracted.
  • the eyeball was fixed and embedded in paraffin to prepare a specimen for optical microscopic examination and cut into slices 3 ⁇ m in thickness.
  • the resultant pathological slice was stained by Luna stain, its part where most infiltration of conjunctival eosinocytes was observed was selected, and the number of eosinocytes in 5 fields were counted which were not overlapped with one another under an optical microscope (magnifying power: 400) .
  • the mean of the counts of the 5 fields was calculated (cells/0.04 mm 2 ) to evaluate the medicine.
  • the medicine was instilled in one eye at a dosage of 10 ⁇ l at 3, 2, 1 and 0.5 hour prior to challenge of conjunctivitis, respectively.
  • Fig. 2 is a graph illustrating inhibitory effect of pranlukast on conjunctival eosinocyte infiltration in guinea pig allergic conjunctivitis.
  • the values in the graph represent the mean ⁇ standard error.
  • the symbol ** represents the significant difference from physiological saline solution, p ⁇ 0.01.
  • pranlukast showed significant inhibitory effect on conjunctival eosinocyte infiltration in the delayed type reaction.
  • an aqueous solution for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous solution for eye drops and nasal drops having the following formulation was prepared.
  • Tyloxapol 4.0 g Sodium chloride 0.9 g 0.1 N sodium hydroxide q.s.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous solution for an injectable preparation having the following formulation was prepared.
  • an aqueous suspension for an internal medicine having the following formulation was prepared.
  • an aqueous suspension for an internal medicine having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
  • an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

In order to promote solubilization or suspension of 4-oxo-8-[4-(4-phenylbutoxy)benzoylamino]-2-(tetrazol-5-yl)-4H-1-benzopyran or its hydrate (pranlukast) in water, at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers is formulated together with pranlukast. Thus, it is possible to provide an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.

Description

DESCRIPTION
AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION CONTAINING AS MAIN COMPONENT BENZOPYRAN DERIVATIVE
FIELD OF THE INVENTION The present invention relates to a pharmaceutical composition comprising as a main component 4-oxo-8- [4- (4- phenylbutoxy)benzoylamino] -2- (tetrazol-5-yl) -4H-1-benzopyran or its hydrate. In particular, it relates to an aqueous liquid pharmaceutical composition containing the benzopyran derivative or its hydrate in higher concentration and having good properties.
BACKGROUND OF THE INVENTION 4-Oxo-δ- [4- (4-phenylbutoxy) benzoylamino] -2-
(tetrazol-5-yl) -4H-l-benzopyran is an antagonist toward leukotrienes (LTC4, LTD4, LTE4) and is known to be a medicine having excellent pharmacological activities on various allergic diseases including asthma (JP-A 61-50977) . Its 1/2 hydrate is called as "pranlukast" and is utilized as an anti-allergic medicine. Then, in the field of ophthalmology, it has been proposed to apply such a medicine to allergic eye diseases such as vernal keratoconjunctivitis, etc.
In general, for preparing an aqueous liquid pharmaceutical composition such as water-soluble eye drops, it is considered that a pharmacologically active component should be present in concentration of about 0.01 to 0.1%. However, 4- oxo-8- [4- (4-phenylbutoxy)benzoylamino] -2- (tetrazol-5-yl) -4H-1- benzopyran and its hydrate (hereinafter, they are referred to as "pranlukast" all together, unless otherwise stated) have very low water-solubility, which makes it very difficult to prepare a useful aqueous liquid pharmaceutical composition thereof. Then, the use
of polyvinyl pyrrolidone and β-cyclodextrin has been proposed to solubilize pranlukast (JP-A 8-73353) .
However, even if polyvinyl pyrrolidone, which is a material known to have strongest solubilization power, is used, pranlukast dissolves in water in concentration of, at highest, about 0.01%.
OBJECTS OF THE INVENTION The main object of the present invention is to promote solubilization or suspension of pranlukast in water, thereby providing an aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties.
This object as well as other objects and advantages of the present invention will become apparent to those skilled in the art from the following description with reference to the attached drawings . BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a graph illustrating the relation between hydroxypropylmethyl cellulose (HPMC) concentration and time required for re-dispersion of pranlukast. Fig. 2 is a graph illustrating the results of the test for inhibitory activity on conjunctival eosinocyte infiltration hereinafter.
SUMMARY OF THE INVENTION The present inventors have extensively studied to promote solubilization or suspension of pranlukast in water and, consequently, have found that the desired solubilization or suspension can be obtained by using at least one component selected from surfactants and specific high-molecular weight substances. Thus, the present inventors have succeeded in preparing the desired aqueous liquid pharmaceutical composition containing higher concentration of pranlukast and having good properties, and have completed the present invention.
That is, according to the present invention, there is provided an aqueous liquid pharmaceutical composition which comprises 4-oxo-8- [4- (4-phenylbutoxy) benzoylamino] -2-
(tetrazol-5-yl) -4H-l-benzopyran or its hydrate and at least one component selected from surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers. In particular, one aspect of the aqueous liquid pharmaceutical composition of the present invention is an aqueous solution containing pranlukast and a surfactant . Preferably, the composition further contains a stabilizer. /Another aspect of the aqueous liquid pharmaceutical composition of the present invention is an aqueous suspension containing pranlukast and at least one component selected from the group consisting of water-soluble cellulose derivatives and water-soluble vinyl polymers. Optionally, the suspension may further contain a surfactant. Preferably, the suspension contains a relatively small amount of a surfactant together with the water-soluble high-molecular weight substance.
These aqueous liquid pharmaceutical compositions have good re-dispersibility over a long time and are stable . In addition, they can contain higher concentration of pranlukast. Then, they can be useful as eye drops, nasal drops, injectable preparations, internal medicine and the like and can be used as an eosinocyte infiltration inhibitor.
DETAILED DESCRIPTION OF THE INVENTION
4-OXO-8- [4- (4-phenylbutoxy) benzoylamino] -2-
(tetrazol-5-yl) -4H-l-benzopyran or its hydrate to be used in the present invention is not specifically limited but its 1/2 hydrate available from Ono Pharmaceutical Co., Ltd. as "pranlukast" is suitable for the present invention.
The amount of pranlukast to be formulated in the composition is not specifically limited but, in case of an aqueous solution, it is formulated in an amount of 0.2 w/v% or less, normally, 0.001 to 0.2 w/v%, preferably 0.005 to 0.1 w/v% based on the total weight of the composition and, in case of an aqueous suspension, 0.01 to 5.0 w/v%, preferably 0.1 to 2.0 w/v% based on the total weight of the composition, in terms of its 1/2 hydrate.
The surfactants to be used are at least one member selected from nonionic surfactants, cationic surfactants and anionic surfactants. As the nonionic surfactants, it is preferred to use those having HLB of 10 to 18. Examples of the nonionic surfactants include polyoxyethylene sorbitan fatty acid ester (e.g., Polysorbate 80, Polysorbate 60, Polysorbate 40, etc.), polyoxyethylene hydrogenated castor oil (e.g., polyoxyethylene hydrogenated castor oil 60, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene castor oil 40, etc.), polyoxyethylene alkylphenyl formaldehyde condensate (e.g., Tyloxapol, etc.), polyoxyethylene polyoxypropylene block copolymer (e.g., Poloxamer 188, Poloxamer 403, etc.) and sucrose ester of fatty acid (e.g., Ryutosugar ester P-1570 and S-1570 manufactured by Mitsubishi Chemical Foods), among others.
Examples of the cationic surfactants include quaternary ammonium salt (e.g., benzalkonium chloride, etc.), among others. Examples of the anionic surfactants include alkyl sulfate (e.g., sodium lauryl sulfate, etc.), among others.
The surfactant can be used alone or in combination of two or more thereof and, normally, in case of an aqueous solution, the surfactant (s) are formulated in an amount of 0.5 to 8 w/v%, preferably 1 to 5 w/v%, more preferably 2 to 4 w/v% based on the total weight of the composition. And, in this case, the proportion of the surfactant (s) to pranlukast is such that 5 to 100 parts, preferably 10 to 60 parts by weight of the surfactant (s) are formulated per 1 part of pranlukast (1/2 hydrate) .
In case that the composition is an aqueous suspension, optionally, the surfactant (s) are formulated in an amount of 0.0001 to 0.2 w/v%, preferably 0.001 to 0.2 w/v%, more preferably 0.01 to 0.2 w/v% based on the total weight of the composition together with the water-soluble high-molecular weight substance as described hereinafter. And, in this case, the proportion of the surfactant (s) to pranlukast is such that 0.0001 to 0.2 part, preferably 0.001 to 0.2 part, more preferably 0.01 to 0.2 part by weight of the surfactant (s) are formulated per 1 part of pranlukast (1/2 hydrate) .
In the present invention, when the composition is in the form of an aqueous solution, normally, pH of the composition is adjusted to 6 or higher, preferably 6 to 9, more preferably 6 to 8. Further, in addition to the surfactants, it is preferred to formulate at least one stabilizer selected from anti-oxidants and chelating agents in an amount of about 0.001 to 0.1 w/v%, thereby improving stability of pranlukast.
As such stabilizers, there are, for example, anti- oxidants such as butylated hydroxytoluene, butylated hydroxyanisole, etc. and chelating agents such as sodium edetate, etc . They can be used alone or in combination of two or more thereof .
The water-soluble cellulose derivatives used in the present invention include at least one member selected from methylcellulose, carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, and hydroxypropylmethyl cellulose.
The water-soluble vinyl polymers used in the present invention include at least one member selected from polyvinyl pyrrolidone K25, polyvinyl pyrrolidone K30, polyvinyl pyrrolidone K90, polyvinyl alcohol and carboxyvinyl polymer.
These water-soluble high-molecular weight substances can be used alone or in combination of two or more thereof.
As described above, these water-soluble high-molecular weight substances can be used together with one or more surfactants, thereby further improving re-dispersibility of the aqueous suspension, in particular, after storage.
In the present invention, the water-soluble cellulose derivatives and the water-soluble vinyl polymers function, in particular, as a suspending agent of the aqueous liquid pharmaceutical composition in the form of a suspension. Then, they are formulated in an amount of 0.00001 to 0.1 w/v%, preferably 0.00005 to 0.05 w/v% based on the total weight of the composition. 7λnd, the proportion of the water-soluble high-molecular weight substance (s) to pranlukast is such that 0.0001 to 0.1 part by weight, preferably 0.0005 to 0.02 part by weight of the water-soluble high-molecular weight substance (s) are formulated per 1 part by weight of pranlukast (1/2 hydrate) .
In a liquid pharmaceutical composition, such suspending agent is generally used in concentration ranging from 0.1 to 4 w/v% based on the total weight of the composition. In view of this, it is very surprising that the suspending agent functions even in such a small amount as in the present invention.
When the aqueous liquid pharmaceutical composition is in the form of a suspension, pH of the composition may be within, for example, the range normally employed for eye drops (e.g., pH 4 to 9, preferably pH 5 to 8) .
If necessary, the aqueous liquid pharmaceutical composition may further contain suitable additives, for example, an isotonic agent such as inorganic salt (e.g., sodium chloride, boric acid, potassium chloride, etc.) and polyhydric alcohol (e.g., glycerin, mannitol, sorbitol, etc.); a buffer solution such as borate buffer solution, phosphate buffer solution, acetate buffer solution, citrate buffer solution, Tris buffer solution, etc. and buffer agent such as a ino acid (e.g., glutamic acid, ε -
aminocapronic acid, etc . ) ; a chelating agent such as sodium edetate, citric acid, etc. ; a preservative such as quaternary ammonium salt (e.g., benzalkonium chloridie, benzethonium chloride, etc.), p-hydroxybenzoate (methyl p-hydroxybenzoate, ethyl p- hydroxybenzoate, propyl p-hydroxybenzoate, butyl p- hydroxybenzoate, etc.), sorbic acid, chlorobutanol, sodium edetate, boric acid, etc., and the like. Normally, an isotonic agent can be formulated in an amount of 0.5 to 6.5 w/v% based on the total weight of the composition. Likewise, 0.01 to 1.0 w/v% of a buffer and 0.001 to 0.1 w/v% of a chelating agent can be formulated based on the total weight of the composition.
The aqueous liquid pharmaceutical composition of the present invention can be prepared in the form of an aqueous solution or suspension such as eye drops, nasal drops, injectable preparations, internal medicine and the like according to a per se known method. For example, the composition can be prepared by adding the solubilizing agent and/or suspending agent, a buffer, an isotonic agent and a preservative to sterilized purified water and, if necessary, heating to dissolve them. The desired liquid pharmaceutical composition can be prepared by dissolving or suspending pranlukast in the resultant solution.
The aqueous liquid pharmaceutical composition of the present invention has eosinocyte infiltration inhibitory activity and is useful as an eosinocyte infiltration inhibitor. Then, it can be used for prophylaxis and therapy of seasonal or year-round allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, giant papillary conjunctivitis, contact blephroconjunctivits, keratitis, scleritis, uveitis, eye itch, allergic rhinitis, sneeze, nasal itching, nasal hypersensitivity, nasofrontal eczema, nasal obstruction and the like. In general, the composition is topically or systemically administered once to six times per day at a daily dosage of 20 to 100 μg/ml of pranlukast. The present invention will be further illustrated by the following experiments and preparation examples, but the present invention is not limited to these preparation examples. In the following experiments and preparation examples, "pranlukast" used is the 1/2 hydrate and all the "percents" are by weight unless otherwise stated.
Experiment 1
Study of solubilizing agents of pranlukast
Method
Pranlukast (manufactured by Ono Pharmaceutical Co., Ltd.) was suspended in 0.1% borate buffer (pH 9 or 8) or 0.1% phosphate buffer (pH8or7) at concentration of 0.1 w/v% . Likewise, pranlukast was suspended in each 0.5% solution of surfactants
(polysorbate 80, polysorbate 60, polysorbate 40, polyoxyethylene hydrogenated castor oil 60, Tyloxapol, benzalkonium chloride, and sodium lauryl sulfate) , water-soluble vinyl polymers (polyvinyl pyrrolidione K30, and polyvinyl alcohol) , cyclodextrins (β- cyclodextrin, y -cyclodextrin, and 2HP-β-cyclodextrin) and
caffeine in 0.1% phosphate buffer (pH 7) at concentration of 0.1 w/v% . Each suspension was filled in a glass ampoule and was shaken overnight (for about 15 hours) at 25°C. After shaking, the suspension was filtered through a membrane filter of 0.45 μm pore size and pranlukast in the filtrate was determined by HPLC.
Results
Solubility of pranlukast is shown in Table 1.
Table 1
Figure imgf000013_0001
As seen from Table 1, solubility of pranlukast in the buffer was increased with the rise of pH. Further, solubility of pranlukast was increased by addition of the surfactants, water-soluble vinyl polymers, cyclodextrin and caffeine. Experiment 2
Relation between solubilization of pranlukast and pH, when using polysorbate 80 as the solubilizing agent Method
Polysorbate 80 was dissolved in 0.1% phosphate buffer and/or 0.1% acetate buffer at concentration of 0.5%. Pranlukast
(manufactured by Ono Pharmaceutical Co., Ltd.) was suspended in the resultant solution at concentration of 0.2% and pH was adjusted to 5 to 8 with sodium hydroxide or hydrochloric acid. Each suspension was filled in a glass ampoule and shaken overnight (for about 15 hours) at25°C. After shaking, the suspension was filtered with a membrane filter of 0.22 μm pore size and pranlukast in the filtrate was determined by HPLC.
Results
Solubility of pranlukast is shown in Table 2. As the rise in pH, solubility of pranlukast was increased.
A difference in buffers was scarcely observed. Table 2
Figure imgf000015_0001
Experiment 3 Relation between concentration of polysorbate 80 and polyoxyethylene hydrogenated castor oil 60, and solubility of pranlukast
Method
Polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 (hereinafter abbreviated as HCO-60)was dissolved in 0.1% phosphate buffer at concentration of 1.0%, 2.0%, 3.0% or 4.0%. Pranlukast (manufactured by Ono Pharmaceutical Co., Ltd.) was suspended in the resultant solution at concentration of 0.2%. Each suspension was filled in a glass ampoule and shaken overnight (for about 15 hours) at25°C. After shaking, the suspension was filtered with a membrane filter of 0.22 μm pore size and pranlukast in the filtrate was determined by HPLC. Results Regarding each nonionic surfactant at each concentration, solubility of pranlukast is shown in Table 3 Table 3
Figure imgf000016_0001
As seen from Table 3, solubility of pranlukast was increased as increase in the amount of polysorbate 80 and polyoxyethylene hydrogenated castor oil 60.
Experiment 4
Test for stability of aqueous solution of pranlukast
Method
According to the formulations in Table 4, solutions A to F were prepared. Each solution was filled in a 5 ml-glass ampoule and stored at 60°C for 2 weeks. After 2 weeks, pranlukast in the solution was determined by HPLC and its residual rate was calculated.
Table 4
Figure imgf000017_0001
*: polyoxyethylene hydrogenated castor oil 60 **: butylated hydroxytoluene
Results
The residual rate of pranlukast is shown in Table 5, Table 5
Figure imgf000018_0001
As seen from Table 5, when Tyloxapol and polyoxyethylene hydrogenated castor oil 60 were used as the solubilizing agents (formulations A, B and C) , the residual rate of pranlukast was more than 98% and was stable. When polysorbate 80 was used as the solubilizing agent (formulation D) , although stability of pranlukast was somewhat lowered in comparison with the other surfactants, stability of more than 95% was obtained by adding the stabilizer, BHT or sodium edetate (formulations E and F) .
In each solution, no deposit of any insoluble material was observed. Experiment 5
Relation between concentration of suspending agent and re-dispersibility Method
Solutions of hydroxyporpylmethyl cellulose (hereinafter abbreviated as HPMC) ranging in concentration from
0.0001 to 0.5% were prepared and pranlukast was added thereto at concentration of 0.5%. After standing at 25°C for 4 days, time required for re-dispersion was measured with a variable mix rotor VMR-5 (60 rpm, manufactured by Iuch Co., Ltd.)
Results Fig. 1 illustrates the relation between HPMC concentration and time required for re-dispersion.
As seen from Fig. 1, when concentration of HPMC (X-axis) was within the range of 0.00075 to 0.1%, time required for re- dispersion of suspending particles of pranlukast (Y-axis) was relatively shorter. In addition, no aggregation or caking of suspending particles of pranlukast was observed within this concentration range.
Experiment 6
Test for eye irritation Method
According to the formulations of Table 6, aqueous solutions (formulations G and H)and suspension (formulation J) of pranlukast were prepared. Eye drops of each solution or suspension were applied to Japanese white male rabbits 8 times per day (0.05 ml/once) and eye irritation was evaluated by the naked eye according to Draize method. Table 6
Figure imgf000020_0001
Results
No eye irritation was observed in all the formulations. Experiment 7
Conjunctival eosinocyte infiltration inhibitory activity
Method
1. Animals Hartley male guinea pigs (body weight: about 300 to 500 g) purchased from Japan SLC were used. The animals were bred under conditions of a temperature of 23 ± 2 °C and humidity of 55 ± 15%.
They were maintained on pellets (radiation sterilized Labo G standard manufactured by Nihon Nosan Kogyo) and sterilized water for animals ad libi tum.
2. Test medicine
Pranlukast was suspended in a vehicle containing 0.1% of sodium dihydrogen phosphate, 0.9% of sodium chloride and 0.1% polysorbate 80 (pH 7) at concentration of 1.0%. As a control, physiological saline solution was used.
3. Procedure
The guinea pigs were sensitized by administering a mixture of 10 μg of ovalbumin (hereinafter referred to as OA) and 30 mg of aluminum hydroxide gel intraperitoneally . 14 Days after sensitization, 10 μl of 2.5% OA antigen solution was instilled in both eyes of the guinea pigs to cause conjunctivitis (primary challenge) . Likewise, 24 hours after the primary challenge, 2.5% OA antigen solution was instilled to cause conjunctivitis again (secondary challenge) .
After 6 hours, each guinea pig was slaughtered, the upper and lower lids were removed from the periosteum and the lids together with the eyeball were extracted. According to a conventional manner, the eyeball was fixed and embedded in paraffin to prepare a specimen for optical microscopic examination and cut into slices 3 μm in thickness. The resultant pathological slice was stained by Luna stain, its part where most infiltration of conjunctival eosinocytes was observed was selected, and the number of eosinocytes in 5 fields were counted which were not overlapped with one another under an optical microscope (magnifying power: 400) .
The mean of the counts of the 5 fields was calculated (cells/0.04 mm2) to evaluate the medicine. The medicine was instilled in one eye at a dosage of 10 μl at 3, 2, 1 and 0.5 hour prior to challenge of conjunctivitis, respectively.
Results
The results are shown in Fig. 2.
Fig. 2 is a graph illustrating inhibitory effect of pranlukast on conjunctival eosinocyte infiltration in guinea pig allergic conjunctivitis. The values in the graph represent the mean ± standard error. The symbol ** represents the significant difference from physiological saline solution, p < 0.01. As seen from Fig. 2, pranlukast showed significant inhibitory effect on conjunctival eosinocyte infiltration in the delayed type reaction. Preparation Example 1
Aqueous solution
According to a conventional method, an aqueous solution for eye drops and nasal drops having the following formulation was prepared. Ingredient /Amount
Pranlukast 0.1 g
Sodium dihydrogen phosphate 2 hydrate 0.2 g Polysorbate 80 4.0 g
Butylated hydroxytoluene 0.01 g Sodium edetate 0.01 g
Benzalkonium chloride 0.01 g
Sodium chloride 0.9 g
0.1 N sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 7.0
Preparation Example 2
Aqueous solution
According to a conventional method, an aqueous solution for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount Pranlukast 0.1 g Sodium dihydrogen phosphate 2 hydrate 0.2 g
Polyoxyethylene hydrogenated castor oil 60 2.0 g
Sodium edetate 0.01 g
Benzalkonium chloride 0.01 g
Boric acid 1.5 g
0.1 N sodium hydroxide q.s.
Sterilized purified water up to 100 ml
PH 7.0
Preparation Example 3
Aqueous solution
According to a conventional method, an aqueous solution for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount
Pranlukast 0.1 g Sodium dihydrogen phosphate 2 hydrate 0.2 g
Sodium edetate 0.01 g
Benzalkonium chloride 0.01 g
Tyloxapol 4.0 g Sodium chloride 0.9 g 0.1 N sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 7.0 Preparation Example 4 Aqueous solution According to a conventional method, an aqueous solution for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount
Pranlukast 0.1 g Sodium dihydrogen phosphate 2 hydrate 0.2 g
Polysorbate 80 4.0 g
Butylated hydroxytoluene 0.01 g
Sodium edetate 0.01 g
Benzalkonium chloride 0.01 g Boric acid 1.5 g
Borax 0.3 g
0.1 N sodium hydroxide q.s.
Sterilized purified water up to 100 ml pH 7.0
Preparation Example 5 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount
Pranlukast 1.0 g
Sodium acetate 0.1 g
Hydroxypropylmethyl cellulose 0.005 g Sodium chloride 0.9 g
Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s.
Sterilized purified water up to 100 ml pH 5.0
Preparation Example 6 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount Pranlukast 1.0 g Sodium acetate 0.1 g HCO-60 0.1 g
Sodium chloride 0.9 g Methyl p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g 0.1 N hydrochloric acid q.s. Sterilized purified water up to 100 ml PH 5.0
Preparation Example 7 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient /Amount
Pranlukast 1.0 g
Sodium acetate 0.1 g Tyloxapol 0.1 g
Sodium chloride 0.9 g
Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
Chlorobutanol 0.3 g 0.1 N hydrochloric acid q.s.
Sterilized purified water up to 100 ml pH 5.0
Preparation Example 8 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount Pranlukast 0.5 g
Sodium acetate 0.1 g
Hydroxypropylmethyl cellulose 0.0025 g
Sodium chloride 0.9 g
Methyl p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s.
Sterilized purified water up to 100 ml pH 5.0
Preparation Example 9 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount Pranlukast 0.1 g
Sodium acetate 0.1 g
Hydroxypropylmethyl cellulose 0.0005 g
Sodium chloride 0.9 g Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s.
Sterilized purified water up to 100 ml pH 5.0 Preparation Example 10
Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared. Ingredient Amount
Pranlukast 1.0 g
Sodium acetate 0.1 g
Methyl cellulose 0.005 g
Sodium chloride 0.9 g Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s.
Sterilized purified water up to 100 ml pH 5.0 Preparation Example 11 Aqueous solution
According to a conventional method, an aqueous solution for an injectable preparation having the following formulation was prepared.
Ingredient Amount
Pranlukast 0.1 g
Polysorbate 80 2.0 g
Sodium edetate 0.01 g Mannitol 5.0 g
Citric acid 0.1 g
0.1 N sodium hydroxide q.s.
Injectable distilled water up to 100 ml pH 7.0 Preparation Example 12
Aqueous solution
According to a conventional method, an aqueous solution for an injectable preparation having the following formulation was prepared. Ingredient Amount
Pranlukast 0.1 g
Polyoxyethylene hydrogenated castor oil 60 2.0 g
Glycerin 2.6 g
Torometamol 0.1 g 0.1 N hydrochloric acid q.s.
Injectable distilled water up to 100 ml pH 7.0
Preparation Example 13 Aqueous suspension
According to a conventional method, an aqueous suspension for an internal medicine having the following formulation was prepared.
Ingredient Amount Pranlukast 5.0 g
Polyvinyl pyrrolidone 0.025 g
Sorbic acid 0.2 g
Water up to 100 ml
Preparation Example 14 Aqueous suspension
According to a conventional method, an aqueous suspension for an internal medicine having the following formulation was prepared.
Ingredient Amount Pranlukast 5.0 g
Hydroxypropylmethyl cellulose 0.025 g
Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
Water up to 100 ml Preparation Example 15 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount
Pranlukast 1.0 g
Sodium acetate 0.1 g
Hydroxypropylmethyl cellulose 0.005 g Ryutosugar ester S-1570 0.005 g
Sodium chloride 0.9 g
Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s. Sterilized purified water up to 100 ml pH 5.0
Preparation Example 16 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount
Pranlukast 1.0 g
Sodium acetate 0.1 g Hydroxypropylmethyl cellulose 0.005 g
Sodium lauryl sulfate 0.1 g Sodium chloride 0.9 g
Methyl p-hydroxybenzoate 0.026 g Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s. Sterilized purified water up to 100 ml pH 5.0 Preparation Example 17 Aqueous suspension
According to a conventional method, an aqueous suspension for eye drops and nasal drops having the following formulation was prepared.
Ingredient Amount Pranlukast 1.0 g
Sodium acetate 0.1 g
Hydroxypropylmethyl cellulose 0.005 g
Polysorbate 80 0.01 g Sodium chloride 0.9 g Methyl p-hydroxybenzoate 0.026 g
Propyl p-hydroxybenzoate 0.014 g
0.1 N hydrochloric acid q.s. Sterilized purified water up to 100 ml pH 5.0

Claims

1. An aqueous liquid pharmaceutical composition which comprises 4-oxo-8- [4- (4-phenylbutoxy) benzoylamino] -2- (tetrazol-5-yl) -4H-l-benzopyran or its hydrate and at least one component selected from the group consisting of surfactants, water-soluble cellulose derivatives and water-soluble vinyl polymers .
2. The composition according to claim 1, wherein the surfactant is a member selected from the group consisting of nonionic surfactants, cationic surfactants and anionic surfactants .
3. The composition according to claim 2, wherein the nonionic surfactant has a HLB of 10 to 18.
4. The composition according to claim 3, wherein the nonionic surfactant is a member selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkylphenyl formaldehyde condensate, polyoxyethylene polyoxypropylene block copolymer and sucrose ester of fatty acid.
5. The composition according to claim 2, wherein the cationic surfactant is selected from quaternary ammonium salts.
6. The composition according to claim 2, wherein the anionic surfactant is selected from alkyl sulfates.
7. The composition according to claim 1, wherein the water-soluble cellulose derivative is a member selected from the group consisting of methyl cellulose, carboxymethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and hydroxypropylmethyl cellulose.
8. The composition according to claim 1, wherein the water-soluble vinyl polymer is a member selected from the group consisting of polyvinyl pyrrolidone, polyvinyl alcohol and carboxyvinyl polymer.
9. The composition according to claim 2 which is an aqueous solution comprising the benzopyran derivative or its hydrate and the surfactant.
10. The composition according to claim 9 which contains at most 0.2 w/v% of the benzopyran derivative or its hydrate.
11. The composition according to claim 9 which contains 0.5 to 8 w/v% of the surfactant.
12. The composition according to claim 9 which contains 5 to 100 parts by weight of the surfactant per 1 part by weight of the benzopyran derivative or its hydrate.
13. The composition according to claim 9, wherein its pH is at lowest 6.
14. The composition according to claim 11 further comprising a stabilizer.
15. The composition according to claim 14, wherein the stabilizer is a member selected from antioxidants and chelating agent.
16. The composition according to claim 15, wherein the antioxidant is butylated hydroxytoluene.
17. The composition according to claim 15, wherein the chelating agent is sodium edetate.
18. The composition according to claim 1 which is an aqueous suspension comprising the benzopyran derivative or its hydrate and at least one component selected from the group consisting of water-soluble cellulose derivatives and water- soluble vinyl polymers.
19. The composition according to claim 18 which contains 0.01 to 5.0 w/v% of the benzopyran derivative or its hydrate.
20. The composition according to claim 18 which contains 0.00001 to 0.1 w/v% of the component selected from the group consisting of water-soluble cellulose derivatives and water- soluble vinyl polymers.
21. The composition according to claim 18 which contains 0.0001 to 0.1 part by weight of the component selected from the group consisting of water-soluble cellulose derivatives and water-soluble vinyl polymers per 1 part by weight of the benzopyran derivative or its hydrate.
22. The composition according to claim 18 further comprising a surfactant.
23. The composition according to claim 22, wherein the surfactant is a member selected from the group consisting of nonionic surfactants, cationic surfactants and anionic surfactants .
24. The composition according to claim 22, wherein the nonionic surfactant is a member selected from the group consisting of polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkylphenyl formaldehyde condensate, polyoxyethylene polyoxypropylene block copolymer and sucrose ester of fatty acid.
25. The composition according to claim 22, wherein the anionic surfactant is selected from alkyl sulfate.
26. The composition according to claim 22 which contains 0.0001 to 0.2 w/v% of the surfactant.
27. The composition according to claim 1 having eosinocyte infiltration inhibitory activity.
28. The composition according to claim 27 which is used for treatment of delayed type allergic conjunctivitis.
29. The composition according to claim 1 in the form of eye drops.
30. The composition according to claim 1 in the form of nasal drops.
31. The composition according to claim 1 in the form of an injectable preparation.
32. The composition according to claim 1 in the form of internal medicine.
33. A pharmaceutical composition for inhibiting eosinocyte infiltration which comprises 4-oxo-8- [4- (4- phenylbutoxy) benzoylamino] -2- (tetrazol-5-yl) -4H-l-benzopyran or its hydrate and a pharmaceutically acceptable carrier or diluent.
PCT/JP1998/003172 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative WO1999004790A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DE69819900T DE69819900T2 (en) 1997-07-23 1998-07-15 AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION CONTAINING A BENZOPYRANE DERIVATIVE AS A MAIN COMPONENT
US09/463,211 US6274609B1 (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
AT98932526T ATE254457T1 (en) 1997-07-23 1998-07-15 AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION CONTAINING A BENZOPYRANE DERIVATIVE AS THE MAIN INGREDIENT
KR1020007000683A KR20010022113A (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
CA002296562A CA2296562A1 (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
EP98932526A EP0996442B1 (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/196771 1997-07-23
JP19677197 1997-07-23

Publications (1)

Publication Number Publication Date
WO1999004790A1 true WO1999004790A1 (en) 1999-02-04

Family

ID=16363363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/003172 WO1999004790A1 (en) 1997-07-23 1998-07-15 Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative

Country Status (9)

Country Link
US (1) US6274609B1 (en)
EP (1) EP0996442B1 (en)
KR (1) KR20010022113A (en)
AT (1) ATE254457T1 (en)
CA (1) CA2296562A1 (en)
DE (1) DE69819900T2 (en)
ES (1) ES2206956T3 (en)
TW (1) TW546151B (en)
WO (1) WO1999004790A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428808B1 (en) * 1995-05-23 2002-08-06 Smithkline Beecham P.L.C. Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament
WO2002076432A3 (en) * 2001-03-26 2002-12-12 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
KR100381834B1 (en) * 2000-05-20 2003-04-26 이상득 Solid dispersion system of pranlukast with improved dissolution, and the method thereof
CN102178647A (en) * 2011-04-28 2011-09-14 重庆圣华曦药物研究开发有限公司 Pranlukast injection preparation

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100341498C (en) 2003-01-21 2007-10-10 千寿制药株式会社 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
KR100715355B1 (en) 2005-09-30 2007-05-07 주식회사유한양행 Spray-dried granules containing pranlukast and processes for the preparation thereof
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
KR101739816B1 (en) * 2010-12-01 2017-05-25 주식회사유한양행 Injectable liquid composition or injectable dried powder containing revaprazan or its salt
KR101739815B1 (en) * 2010-12-01 2017-05-26 주식회사유한양행 Injectable liquid composition containing revaprazan or its salt
KR102478553B1 (en) 2018-02-28 2022-12-16 한림제약(주) Eye drop formulation in a solution form comprising a benzopyran derivative or pharmaceutically acceptable salt therof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641569A1 (en) * 1992-03-12 1995-03-08 Ono Pharmaceutical Co., Ltd. Antipruritic
JPH0873353A (en) * 1994-09-02 1996-03-19 Ono Pharmaceut Co Ltd Preparation comprising pranlukast and polyvinylpyrrolidone or beta-cyclodextrin
WO1996041628A1 (en) * 1995-06-12 1996-12-27 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3665166B2 (en) * 1996-07-24 2005-06-29 東京応化工業株式会社 Chemically amplified resist composition and acid generator used therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641569A1 (en) * 1992-03-12 1995-03-08 Ono Pharmaceutical Co., Ltd. Antipruritic
JPH0873353A (en) * 1994-09-02 1996-03-19 Ono Pharmaceut Co Ltd Preparation comprising pranlukast and polyvinylpyrrolidone or beta-cyclodextrin
WO1996041628A1 (en) * 1995-06-12 1996-12-27 Ono Pharmaceutical Co., Ltd. Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9621, Derwent World Patents Index; Class A96, AN 96-205438, XP002081469 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428808B1 (en) * 1995-05-23 2002-08-06 Smithkline Beecham P.L.C. Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament
KR100381834B1 (en) * 2000-05-20 2003-04-26 이상득 Solid dispersion system of pranlukast with improved dissolution, and the method thereof
WO2002076432A3 (en) * 2001-03-26 2002-12-12 Novartis Ag Pharmaceutical composition comprising a poorly water-soluble active ingredient, a surfactant and a water-soluble polymer
CN102178647A (en) * 2011-04-28 2011-09-14 重庆圣华曦药物研究开发有限公司 Pranlukast injection preparation
CN102178647B (en) * 2011-04-28 2012-09-12 重庆圣华曦药物研究开发有限公司 Pranlukast injection preparation

Also Published As

Publication number Publication date
DE69819900D1 (en) 2003-12-24
EP0996442B1 (en) 2003-11-19
EP0996442A1 (en) 2000-05-03
TW546151B (en) 2003-08-11
US6274609B1 (en) 2001-08-14
ES2206956T3 (en) 2004-05-16
CA2296562A1 (en) 1999-02-04
ATE254457T1 (en) 2003-12-15
KR20010022113A (en) 2001-03-15
DE69819900T2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
US6284804B1 (en) Topical suspension formulations containing ciprofloxacin and dexamethasone
JP2004536096A (en) Olopatadine formulation for topical administration
WO2010059894A1 (en) Ocular formulations of norketotifen
EP2002841A1 (en) Ophthalmic composition comprising xanthan gum and glucose
JPH07116029B2 (en) Tranilast aqueous solution formulation
US20090209599A1 (en) Eye drop containing roflumilast
EP0996442B1 (en) Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
EP0659433B1 (en) Ophthalmic suspension containing diflupredonate
US6281224B1 (en) Pranoprofen eyedrops containing organic amine
WO2011018800A2 (en) A novel in-situ gel forming solution for ocular drug delivery
WO2005101982A2 (en) A stable ophthalmic composition
WO2017064732A1 (en) Ophthalmic solution of difluprednate
JP2014111587A (en) Allergy preventive agent for ophthalmology
KR20170080666A (en) Ophthalmic aqueous composition
US20030031718A1 (en) Ophthalmic compositions and use
JP3781792B2 (en) Ophthalmic suspension containing difluprednate
JP2006306877A (en) Dosage form, pharmaceutical composition and method for sub tenon delivery
JP4849288B2 (en) Eye drops and tear film stabilizer
JPH1192368A (en) Aqueous liquid agent containing benzopyran derivative as main component
WO2004103373A1 (en) Ophthalmic solution containing quinolone antimicrobial compound
JP2005008625A (en) Eye lotion containing quinolone-based antibacterial compound
JP2007016024A (en) Roflumilast eye drop
EP1004309A1 (en) Israpafant-containing water-base preparations
EP4248970A1 (en) Opthalmic compositions comprising cetirizine and tocofersolan
WO2013055073A2 (en) Ophthalmic composition containing cyclosporine and method for preparing same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2296562

Country of ref document: CA

Ref country code: CA

Ref document number: 2296562

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998932526

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09463211

Country of ref document: US

Ref document number: 1020007000683

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1998932526

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007000683

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998932526

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007000683

Country of ref document: KR